Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

Area of Science:

• Nuclear medicine
• Radiopharmaceutical science
• Oncology

Background:

• Targeted alpha-particle therapy (TAT) offers a potent approach to cancer treatment due to the high energy and short range of alpha particles.
• Significant advancements have been made in radionuclide production, targeting vectors, and delivery systems for TAT.

Purpose of the Study:

• To review recent progress and challenges in targeted alpha-particle therapy.
• To discuss radionuclide production, delivery strategies, and radiopharmaceutical considerations for alpha emitters.
• To highlight achievements and future outlook in preclinical and clinical TAT applications.

Main Methods:

• Comprehensive literature review of targeted alpha-particle therapy.
• Analysis of radionuclide production (e.g., 211At, 223Ra, 225Ac/213Bi).
• Evaluation of targeting vectors (small molecules, chelators, nanocarriers) and delivery methods.
• Review of preclinical studies and clinical trials, including dose estimation and imaging.

Main Results:

• Progress in producing and labeling alpha-emitting radionuclides for targeted delivery.
• Development of various vectors, including small molecules, chelators, and nanocarriers, for effective tumor targeting.
• Insights into nuclear recoil effects, dose estimation, and radiopharmaceutical challenges impacting clinical translation.
• Successful preclinical and early clinical applications demonstrating the potential of TAT.

Conclusions:

• Targeted alpha-particle therapy is a rapidly advancing field with significant potential for cancer treatment.
• Overcoming challenges in radionuclide production, delivery, and dosimetry is crucial for widespread clinical adoption.
• Continued research and development in TAT, including novel vectors and imaging techniques, will drive future therapeutic successes.